Hormone therapy for stapedoplasty in patients with otosclerosis

Surgical treatment of hearing loss due to otosclerosis is characterized by high clinical efficacy and ensures achievement of an air-bone gap of ≤10 dB in 58-97% of patients. However, acute sensorineural hearing loss as a complication of stapedoplasty occurs in 0.2-0.95% of cases after the primary intervention, in 2.9% after revision stapedoplasty and in 4.8% with the obliterating otosclerosis....

Continue reading at PubMed →

Insufficient detail is available from this abstract to recommend adopting hormone therapy as a routine adjunct to stapedoplasty; surgeons should await full peer-reviewed results before changing practice.

Sensorineural complications remain the most feared outcome of stapedoplasty, so any adjunct therapy that could reduce that risk or improve hearing outcomes would be clinically significant for otologic surgeons and their audiology teams.

1. 01Stapedoplasty achieves an air-bone gap ≤10 dB in 58–97% of cases, but sensorineural complications remain a risk.
2. 02The study investigated hormone therapy as an adjunct to stapedoplasty in otosclerosis patients.
3. 03Otosclerosis is a condition of abnormal middle-ear bone growth leading to conductive hearing loss.
4. 04Published in Vestnik Otorinolaringologii (2026); full outcome data not available in the abstract.
5. 05Potential relevance to peri-operative management protocols in otologic surgery.

PMID

42693982

DOI

10.17116/otorino20269104122.

Journal

Vestnik Otorinolaringologii

Publication type

research_article

Evidence level

4

Population

Patients with otosclerosis undergoing stapedoplasty

Intervention

Hormone therapy as an adjunct to stapedoplasty

Comparator

Stapedoplasty without hormone therapy